We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

ReproCELL Establishes European Headquarters Following Merger

ReproCELL Establishes European Headquarters Following Merger

ReproCELL Establishes European Headquarters Following Merger

ReproCELL Establishes European Headquarters Following Merger

Read time:

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "ReproCELL Establishes European Headquarters Following Merger"

First Name*
Last Name*
Email Address*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

The Japanese regenerative medicine company ReproCELL Inc., has announced that two of its Group companies, Biopta and Reinnervate, will merge to form a new company, ReproCELL Europe Ltd.  The merger is aimed at strengthening ReproCELL’s pharmaceutical industry-targeted drug discovery services and products through the integration of Biopta’s human tissue services with Reinnervate’s stem cell and 3D cell culture expertise.  ReproCELL Europe will operate from new headquarters in Glasgow, UK, with an established production and distribution site in Sedgefield, UK.  

ReproCELL Europe aims to grow the workforce significantly over the next three years and plans to move to larger premises in Glasgow within the next nine months.  ReproCELL Europe’s management team views the synergies within the ReproCELL Group companies as key to its growth ambitions.  

Dr David Bunton, Biopta’s co-founder and now CEO of ReproCELL Europe, said: “The merger of the two UK companies is a great opportunity to build on the solid platform Biopta has in outsourced drug discovery services and combine this with Reinnervate’s expertise in 3D cell culture and stem cell technology.  As the drug market moves towards a personalised medicine approach, this will allow our company to increase our market share by expanding our range of human tissue drug discovery assays aimed at the pharmaceutical industry, and also accelerate the development of ReproCELL’s new iPSC products and services.”

ReproCELL, a leader in the field of stem cells and regenerative medicine, was established in 2003 with the goal of contributing to people’s health and welfare through the development of stem cell technologies.  Many of ReproCELL’s technologies were developed by the stem cell pioneers, Prof. Norio Nakatsuji from the Institute for Integrated Cell-Material Sciences, Kyoto University, and Prof. Hiromitsu Nakauchi from The Institute of Medical Sciences, The University of Tokyo.  

ReproCELL’s CEO, Dr. Chikafumi Yokoyama, said of the merger: “This is an exciting development for ReproCELL and crucial for our expansion into the European market.  Scotland is one of Europe’s top locations for stem cell research and we feel our European headquarters will be ideally placed for expansion of our stem cell products and services.” 

Julia Brown, Director of Life and Chemical Sciences at Scottish Enterprise, said: “We are delighted to see international investors enable two UK companies to grow within a larger global organisation.  The companies have clear synergies and complementary offerings and we’re sure as ReproCELL Europe, they will continue to serve the needs of both the academic and pharmaceutical development community.  We are equally delighted at the new company’s decision to establish its European headquarters in Scotland which will create new jobs and reinforce Scotland’s reputation as an attractive and competitive location for global life science companies.”